Effect of drug combinations on admission for recurrent myocardial infarction

Heart

Volumn 93, Issue 10, 2007, Pages 1226-1230

  Van Der Elst, Menno E ^a   Bouvy, Marcel L ^a,b   De Blaey, Cornells J ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; DRUG COMBINATIONS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; NETHERLANDS; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; RECURRENCE; REGRESSION ANALYSIS;

EID: 34848868773     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.098053     Document Type: Article

References (27)

1. Anonymous. Demographic Yearbook 1997, English/French ed. New York: Publishing Division United Nations, 1998.
2. AHA. 2002 Heart and stroke statistical update. Dallas: American Heart Association, 2001. http://www.americanheart.org (accessed 27 October 2005).
3. Statline. Population, monthly and yearly data. Statistics Netherlands, http://statline.cbs.nl (accessed 27 October 2005).
4. Antithrombotics trialist collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. Freemantle N, Cleland J, Young P, et al. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
6. Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. BMJ 1998;316:838-42.
7. van der Elst ME, Buurma H, Bouvy ML, et al. Drug therapy for prevention of recurrent myocardial infarction. Ann Pharmacother 2003;37:1465-77.
8. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
9. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104:522-6.
10. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
11. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Inlern Med 1993;153:345-53.
12. Dargie HJ. Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
15. van Bergen PF, Deckers JW, Jonker JJ, et al. Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. Br Heart J 1995;74:117-21.
16. Smith P, Arnesen H, Abdelnoor M. Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction. Arch Intern Med 1992;152:993-7.
17. Pyorala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31.
18. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9.
19. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
20. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 2005;330:1059-63.
21. Herings RM, Bakker A, Strieker BH, et al. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992;46:136-40.
22. Institute for Drug Outcome Research. The Pharmo Database. Pharmo Institute. http://www.pharmo.nl (accessed 27 October 2005).
23. Manlel-Teeuwisse AK, Klungel OH, Verschuren WM, et al. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 2001;54:1181-6.
24. Herings RM, de Boer A, Stricker BH, et al. A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharm World Sci 1995;17:17-9.
25. Mairland-van der Zee AH, Klungel OH, Strieker BH, et al. Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. Pharm World Sci 2003;25:70-2.
26. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1.
27. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989-91.